To order sections of the reports, contact Client Services.

This model contains ten-year commercial forecasts for hepatitis B drug sales by class, molecule and brand for the US, Japan, France, Germany, Italy, Spain, UK and Turkey.

Reasons to Purchase

• Understand the changing market dynamics of hepatitis B drugs, and success factors for leading brands....
  

In 2009, HIV antiretrovirals sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10....

Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers....

Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%....

Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers....

Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies to improve survival rates in patients presenting with both localized and advanced disease....

Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form of inflammatory arthritis associated with psoriasis, whilst ankylosing spondylitis causes arthritis of the spine and sacroiliac joints....

Introduction

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2018. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0....

Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures to help reduce the impact of the impending 2011 patent cliff. To fill pipeline voids with new products, companies continue to make acquisitions and form partnerships with small pharma, biotech companies and academia, although the relationships between each are becoming increasingly dynamic....

Introduction

The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. However, the shift toward a more personalized approach means fewer drugs will achieve blockbuster status....

Introduction

Androgen deprivation therapies (ADTs) are the main treatment type for hormone-sensitive prostate cancer. As the disease is hormonally fuelled, chemical castration provides adequate disease control for a number of years....

Introduction

The diagnosed type 2 diabetes population continues to rise on the back of aging and obesity rates, expanding the market potential for modern insulins. Biosimilar modern insulins are forecast to impact seven major market sales from 2014, raising new barriers for market entry.

Features and benefits

• Forecast leading insulin antidiabetic brands in the 2011–20 period
• Quantify the sales potential of late-stage pipeline products Degludec and Degludec Plus
• Assess the impact of biosimilar competition on insulin analog brands
• Determine the impact of recent clinical trial results and regulatory decisions

Introduction

The 2011–20 forecast period will see the loss of exclusivity for the leading non-insulin antidiabetic Actos franchise, while new launches include the first once-weekly GLP-1 agonists and the oral SGLT-2 inhibitor class, to compete in an increasingly crowded treatment algorithm in type 2 diabetes.

Features and benefits

• Forecast leading non-insulin antidiabetic brands in the 2011–20 period
• Quantify the sales potential late-stage pipeline products
• Assess the impact of generic competition and sales restrictions on the Actos (pioglitazone) franchise
• Determine the impact of recent clinical trial results and regulatory decisions

Introduction

Four new product launches in prostate cancer over the next 10 years, including Medivation’s androgen receptor inhibitor MDV3100 and Takeda’s 17, 20 lyase inhibitor TAK-700 will counter generic erosion. In addition Increasing use of Zytiga (abiraterone; Johnson&Johnson) and Jevtana (cabazitaxel;Sanofi) will boost market value from $1....

Introduction

Erosion of the multibillion dollar angiotensin receptor blocker (ARB) class began in 2010 when losartan generics entered the US market. A multitude of antihypertensive fixed-dose combinations have recently been launched in an attempt to secure revenue streams.

Features and benefits

• Forecast leading antihypertensive brands in the 2011–20 period
• Quantify the sales potential late-stage pipeline products
• Assess the impact of key patent expiries, such as Novartis’s Diovan (valsartan)
• Determine the impact of recent clinical trial results and ongoing trials

Introduction

The majority of the drugs in the late stage of the pipeline are being developed to target Gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Progress has been slow, with many drugs held up by the US FDA's changing guidance on the design of antibiotic clinical trials....

This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Asia Pacific pharmaceutical market.

The report provides a worldwide strategic overview of the pharmaceutical market, including: